Corticosteroid-sparing treatments in patients with Crohn's disease

American Journal of Gastroenterology

Volumn 97, Issue 7, 2002, Pages 1607-1617

  Plevy, Scott E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG INDUCED DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL;

EID: 0036317865     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04174-6     Document Type: Review

References (74)

1. Trends in incidence rates of ulcerative colitis and Crohn's disease
2. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen
3. Epidemiology and the natural course of inflammatory bowel disease
4. Indications for surgery in inflammatory bowel disease
5. National Cooperative Crohn's Disease Study (NCCDS): Results of drug treatment
6. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
7. Frequency of glucocorticoid resistance and dependency in Crohn's disease
8. Management of complications of glucocorticoid therapy
9. Methotrexate for the treatment of Crohn's disease
10. Clinical experience with infliximab therapy in 100 patients with Crohn's disease
11. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
12. Treatment of Crohn's disease with 6-mercaptopurine
13. Infliximab in Crohn's disease: First anniversary clinical experience
14. Medical therapy for inflammatory bowel disease
15. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease
16. A comparison of budesonide with prednisolone for active Crohn's disease
17. Management of Crohn's disease in adults
18. Oral budesonide as maintenance treatment for Crohn's disease: A placebo controlled, dose-ranging study
19. Budesonide prolongs time to relapse in ileal and ileo-cecal Crohn's disease. A placebo controlled one year study
20. Low dose steroids and clinical relapse in Crohn's disease: A controlled trial
21. Corticosteroids for maintaining remission of Crohn's disease
22. Cytokine modulation by glucocorticoids: Mechanism and actions in cellular studies
23. Corticosteroid treatment in active Crohn's disease
24. Glucocorticoid-induced osteoporosis: Pathogenesis and management
25. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease
26. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease
27. Users of low dose glucocorticoids have increased bone loss rates: A longitudinal study
28. Metabolic bone disease in adults with inflammatory bowel disease
29. Steroid-related osteonecrosis in inflammatory bowel disease
30. Glucocorticoids and the risk for initiation of hypoglycemic therapy
31. Corticosteroid-associated complications in elderly Crohn's disease patients
32. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure
33. Use of inhaled corticosteroids and the risk of cataracts
34. Risk of infectious complications in patients taking glucocorticosteroids
35. The safety of corticosteroid therapy in Crohn's disease with an abdominal mass
36. Influence of steroid treatment's duration in patients with active Crohn's disease
37. Oral budesonide for active Crohn's disease
38. A comparison of budesonide and mesalamine for active Crohn's disease
39. Oral budesonide is as effective as oral prednisolone in active Crohn's disease
40. Switch from systemic steroids to budesonide in steroid-dependent patients with inactive Crohn's disease
41. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
42. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial
43. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study
44. A controlled double blind study of azathioprine in the management of Crohn's disease
45. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease (Cochrane Review)
46. A controlled trial of azathioprine in Crohn's disease
47. Doubleblind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
48. Controlled trial of azathioprine in Crohn's disease
49. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis
50. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
51. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
52. Treatment of Crohn's disease with azathioprine: A controlled evaluation
53. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
54. 6-Mercaptopurine in the management of inflammatory bowel disease: Shortand long-term toxicity
55. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 Years of experience
56. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
57. Methotrexate in chronic active Crohn's disease: A double-blind, randomized, Israeli multicenter trial
58. Methotrexate in Crohn's disease: Results of a randomized, double-blind placebo-controlled trial
59. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring drug toxicity
60. Low-dose cyclosporine for the treatment of Crohn's disease
61. Oral cyclosporin for chronic active Crohn's disease. A multicentre controlled trial
62. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study
63. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease
64. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
65. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
66. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
67. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
68. Review article: Safety of infliximab in clinical trials
69. Long term safety of infliximab
70. Long-term follow-up of patients treated with infliximab (anti-TNFA antibody) in clinical trials
71. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
72. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease
73. A randomized controlled trial of CDP571, a humanized antibody to TNFA, in moderately and severely active Crohn's disease
74. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis